Ocugen (OCGN) stock tanked over 14% in premarket trading after announcing mixed results from its Phase 2 trial for dry AMD. The company reported that its drug, OCU410, significantly reduced lesion growth, which investors found disappointing. The drop reflects concerns over the drug's future prospects despite the positive trial metrics.